Retifanlimab

Records for this ingredient, by country (identity only).

ATC L01FF10 · 5 markets · 5 records

Retifanlimab 5 markets · 5 records Forms
Filters
MarketUS 1CA 1JP 1EU 1

US 1 records · 1 shown of 1 Source openFDA NDC Directory · Data as of 2026-10-23

  • 25 mg per mL / per unit basis not statedinjectionZYNYZ

CA 1 records · 1 shown of 1 Source Health Canada Drug Product Databas · Data as of 2026-10-23

  • 25 mg per mL / per unit basis not statedliquidZYNYZ

JP 1 records · 1 shown of 1 Source 厚生労働省 薬価基準収載品目リスト · Data as of 2026-11-01

  • 500 mg/20 mLinjectionジニイズ点滴静注500mg

EU 1 records · 0 shown of 0 Source European Commission · Data as of 2026-11-03 · some records have no stated strength

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名ZYNYZ ×1

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.